Doxorubicin Cardiotoxicity Involving Nrf2 Signaling Exhaustion and Myocardial Ferroptosis Sensitization

Explore how doxorubicin induces cardiotoxicity via Keap1-Nrf2 axis collapse, labile iron pool expansion, and 4-HNE-dependent myocardial ferroptosis.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    In the H9c2 rat cardiomyocyte model, this futile redox cycle operates with a Michaelis constant (Km) of approximately 10 to 20 μM, leading to acute respiratory control ratio collapse [1].
  • 2
    The endogenous response to doxorubicin exposure displays biphasic activation-to-repression kinetics centered on the Kelch-like ECH-associated protein 1 (Keap1) and nuclear factor erythroid 2-related factor 2 (Nrf2) axis [3][4].
  • 3
    Disruption of homeostatic iron sequestration constitutes the second obligate event in doxorubicin-induced myocardial pathogenesis [1][7].
  • 4
    Loss of Nrf2 activity arrests de novo GPX4 transcription, while the direct depletion of its essential cofactor, GSH, renders catalytic selenocysteine (Sec46) vulnerable to irreversible oxidative inactivation [6].
  • 5
    Under continuous, clinically relevant doxorubicin exposures (0.1–0.5 μM), dying cardiomyocytes exhibit no canonical genomic DNA cleavage ladders and lack active, cleaved caspase-3 or caspase-9 fragments [8].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
EXTRACELLULAR MEMBRANE CYTOPLASM NUCLEUS PATHWAY CASCADE — Doxorubicin (Adriamycin) P=Phospho | ->=Activate | -|=Inhibit Doxorubicin Km 10-20 µM TfR1 FPN1 SLC7A11 Fe²⁺ NCOA4 P FTH1 ROS Keap1 GSK-3β P Nrf2 P GSH GPX4 Top2β Nrf2 ARE
Proposed Mechanism of Action and Downstream Signaling Pathway Cascade of Doxorubicin (Adriamycin) Driven Cardiotoxicity.

A multi-compartment molecular pathway diagram displaying: 1) Sarcoplasm and Mitochondria, where doxorubicin undergoes futile redox cycling to a semiquinone radical, generating superoxide and destabilizing cardiolipin. 2) Nucleus, showing initial transient Keap1 oxidation superseded by GSK-3β/β-TrCP-dependent degradation and PRMT4-mediated methylation of Nrf2, halting SLC7A11 and GPX4 gene transcription. 3) Autolysosome, where NCOA4-mediated ferritinophagy degrades FTH1 to elevate the labile iron pool. 4) Sarcolemma and Organelle Membranes, wherein ACSL4/LPCAT3 enrich polyunsaturated phosphatidylethanolamines (PE-PUFAs) that undergo Fenton-driven peroxidation into 4-HNE adducts, triggering outer mitochondrial membrane rupture and non-apoptotic cardiac death.

Redox Cycling and Mitochondrial Bioenergetic Collapse

Doxorubicin-mediated cardiotoxicity originates from single-electron reduction of its quinone moiety by mitochondrial NADH dehydrogenase (Complex I) and NADPH-dependent oxidoreductases, producing a transient semiquinone radical intermediate [1]. This semiquinone rapidly shifts an electron onto molecular oxygen, yielding continuous fluxes of superoxide anions (O₂^{\bullet-}) and hydrogen peroxide (H₂O₂) while regenerating the parent quinone backbone [1][2]. In the H9c2 rat cardiomyocyte model, this futile redox cycle operates with a Michaelis constant (Km) of approximately 10 to 20 μM, leading to acute respiratory control ratio collapse [1]. Doxorubicin demonstrates stereochemical avidity toward the inner mitochondrial membrane, binding cardiolipin with an association constant (Ka) of 1.6 × 10[6] M^-1 [2]. This stable lipid-drug interaction uncouples oxidative phosphorylation, mobilizes cytochrome c into the intermembrane space, and impairs ATP synthesis [2][3].

Concurrently, doxorubicin forms a ternary cleavage complex with Topoisomerase IIβ (Top2β) in quiescent post-mitotic cardiomyocytes, triggering unrepaired DNA double-strand breaks and transcription factor arrest, a genotoxic signature distinct from Topoisomerase IIα inhibition in rapidly dividing neoplastic cells [2]. Table 1 benchmarks the operational binding kinetics, redox generation metrics, and enzymatic parameters of doxorubicin against reference cardioprotective interventions across preclinical models. The selective retention of doxorubicin within cardiac mitochondria, compounded by limited endogenous catalase and superoxide dismutase activity in cardiomyocytes, shifts intracellular equilibrium toward unchecked oxidative stress [1][3]. These bioenergetic and enzymatic perturbations precede downstream transcriptional alterations, establishing an oxidative microenvironment that directly destabilizes primary cardiomyocyte survival networks.

Biphasic Keap1-Nrf2 Dysregulation and Antioxidant Collapse

The endogenous response to doxorubicin exposure displays biphasic activation-to-repression kinetics centered on the Kelch-like ECH-associated protein 1 (Keap1) and nuclear factor erythroid 2-related factor 2 (Nrf2) axis [3][4]. Under acute, sub-micromolar challenge (0.1–0.3 μM), reactive oxygen species covalently modify sensor cysteines (Cys151, Cys273, Cys288) on Keap1, disrupting Cullin 3 (Cul3)-dependent polyubiquitination and promoting transient Nrf2 nuclear accumulation [3]. Nevertheless, persistent doxorubicin exposure terminates this defensive pathway [4][5]. In C57BL/6 mouse myocardium, extended drug presence induces tripartite motif-containing 21 (TRIM21), an E3 ubiquitin ligase that targets p62/SQSTM1 for proteasomal degradation, thereby freeing Keap1 to sequester and degrade de novo Nrf2 [3].

Parallel post-translational modifications accelerate this transcriptional shutdown. Doxorubicin activates glycogen synthase kinase-3 beta (GSK-3β), which phosphorylates serine residues within the Neh6 domain of Nrf2, creating a degradation motif recognized by the β-TrCP/Cul1 ubiquitin ligase complex independent of Keap1 [4][5]. Concurrently, protein arginine methyltransferase 4 (PRMT4)-dependent methylation of Nrf2 restricts its nuclear translocation capacity [6]. Transcriptional suppression of the Antioxidant Response Element (ARE) battery ensues: expression of the catalytic and modifier subunits of glutamate-cysteine ligase (GCLC, GCLM) and solute carrier family 7 member 11 (SLC7A11, the core antiporter subunit of system Xc⁻) plummets by more than 70% within 48 hours [6][7]. Total intracellular glutathione (GSH) reserves drop below 20% of basal concentrations, leaving the myocardium defenseless against lipid peroxidation [4][7].

Labile Iron Pool Expansion and Ferritinophagy Activation

Disruption of homeostatic iron sequestration constitutes the second obligate event in doxorubicin-induced myocardial pathogenesis [1][7]. Doxorubicin directly perturbs iron-regulatory proteins 1 and 2 (IRP1/2) post-transcriptionally, binding critical hairpin loops in iron-responsive elements (IREs) on target mRNAs [8]. This structural interference drives sustained upregulation of transferrin receptor 1 (TfR1) alongside down-regulation of the primary basolateral iron exporter ferroportin (FPN1), inducing net unidirectional iron influx into cardiac sarcoplasm [1][8]. In primary cardiomyocytes, these transport anomalies escalate basal cytosolic labile iron pool (Fe²⁺) levels three- to five-fold within 24 hours of exposure [1].

Sustained oxidative stress accelerates nuclear receptor coactivator 4 (NCOA4)-mediated autophagic clearance of iron storage complexes, termed ferritinophagy [7][8]. Phosphorylated NCOA4 binds the conserved surface loop of ferritin heavy chain 1 (FTH1) with high affinity, delivering iron-laden ferritin nanocages into acidic autolysosomes for hydrolytic degradation [7]. The subsequent release of unchelated ferrous iron (Fe²⁺) overwhelms residual cytoplasmic chelating proteins [8]. Unrestricted ferrous iron engages in relentless intracellular Fenton cascades (Fe²⁺ + H₂O₂ → Fe³⁺ + ^{\bulletOH + OH^-}), producing hydroxyl radicals whose diffusion distance is limited only by immediate collision with membrane phospholipids [1][8]. In the zebrafish model, genetic suppression of ferritinophagy or pharmacological chelation prevents doxorubicin-mediated iron accumulation and preserves contractile fractional shortening, confirming that unsequestered iron serves as the catalytic driver of cardiomyocyte demise [2].

GPX4 Depletion and Electrophilic 4-HNE Adduct Accrual

The lethal intersection of cellular glutathione depletion and labile iron accumulation manifests as a systemic failure of phospholipid hydroperoxide detoxification [6][8]. Glutathione peroxidase 4 (GPX4), the sole selenoprotein enzyme capable of reducing esterified phospholipid hydroperoxides (PLOOH) to non-toxic lipid alcohols (PLOH) within biological membranes, undergoes dual transcriptional and post-translational elimination [8]. Loss of Nrf2 activity arrests de novo GPX4 transcription, while the direct depletion of its essential cofactor, GSH, renders catalytic selenocysteine (Sec46) vulnerable to irreversible oxidative inactivation [6]. Doxorubicin treatment drives GPX4 enzymatic activity down by >80% in Sprague-Dawley rat ventricular tissue, setting a permissive threshold for lethal lipid autoxidation [9].

Simultaneously, doxorubicin activates acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3), selectively incorporating polyunsaturated fatty acids (PUFAs)—predominantly arachidonic acid (AA, C20:4) and adrenic acid (AdA, C22:4)—into membrane-bound phosphatidylethanolamines (PE-PUFAs) [6]. Ferrous iron catalyzes radical abstraction of bis-allylic hydrogens from these PE-PUFAs, triggering an autoperoxidative chain reaction that generates toxic phospholipid hydroperoxides (PE-AA-OOH, PE-AdA-OOH) [6][8]. Degradation of these peroxides yields abundant α,β-unsaturated reactive aldehydes, including 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) [6][9]. Electrophilic 4-HNE forms irreversible covalent Michael adducts with nucleophilic histidine, cysteine, and lysine residues on sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase 2a (SERCA2a) and cardiac troponin I (cTnI) [9]. These protein-lipid adducts disrupt calcium reuptake kinetics and mechanical tension generation, precipitating systolic left ventricular dysfunction.

Ultrastructural Christolysis and Non-Apoptotic Terminal Rupture

The terminal phase of doxorubicin cardiomyopathy displays morphological and biochemical hallmarks that diverge from canonical apoptosis and receptor-mediated necroptosis [8][9]. Under continuous, clinically relevant doxorubicin exposures (0.1–0.5 μM), dying cardiomyocytes exhibit no canonical genomic DNA cleavage ladders and lack active, cleaved caspase-3 or caspase-9 fragments [8]. Pan-caspase inhibitors, such as z-VAD-FMK, and receptor-interacting protein kinase 1 (RIPK1) inhibitors, such as necrostatin-1, fail to rescue cell viability or halt biomarker release [8][9]. The dominant cell death modality conforming to this pharmacological profile is ferroptosis, driven by unresolved iron-dependent peroxidative destruction of cellular membranes [6][8].

Transmission electron microscopy (TEM) of myocardium from doxorubicin-treated Balb/c mice reveals distinctive organellar lesions: dysmorphic mitochondria featuring outer membrane rupture, widespread disintegration of cristae (christolysis), and electron-dense condensation of the internal matrix, without chromatin marginalization or apoptotic blebbing [6][9]. Pharmacological administration of lipophilic radical-trapping antioxidants (RTAs) such as ferrostatin-1 and liproxstatin-1, or catalytic iron chelators like dexrazoxane and deferoxamine, completely suppresses these ultrastructural abnormalities and restores ejection fraction and fractional shortening [2][6][9]. Similarly, the small-molecule isoflavone tectorigenin restores the p62-Keap1-Nrf2/GPX4 cascade, demonstrating that stabilizing the endogenous antioxidant transcriptional response terminates 4-HNE production and structural christolysis in H9c2 cells [9]. These empirical interventions confirm that doxorubicin-induced cardiotoxicity represents an actionable ferroptotic execution program driven by transcriptional exhaustion of the Nrf2 signaling network.

Table 1. Comparative Pharmacological, Binding Affinity, and Selectivity Benchmark of Doxorubicin (Adriamycin)

Pharmacological Parameter / Biological AssayDoxorubicin (Adriamycin)Dexrazoxane (ICRF-187)Ferrostatin-1 (Fer-1)Biological Significance & Mechanistic Impact
Target Affinity / Modulatory Potency (Kd / IC50)Ka = 1.6 × 10^6 M^-1 (Cardiolipin)IC50 = 2.4 μM (Top2 catalytic)EC50 = 60 nM (Lipid peroxidation)Quantifies membrane retention versus enzymatic topoisomerase and radical-trapping capacity
Mitochondrial NADH Dehydrogenase Km10–20 μM (Complex I)Inactive (>100 μM)Inactive (>100 μM)Reflects direct semiquinone redox cycling and mitochondrial superoxide flux generation
Labile Iron Pool Expansion Factor (24h)3.5- to 5.0-fold increaseSuppressed (<1.2-fold)Unaltered (3.2-fold)Measures expansion of free ferrous iron available for cytosolic Fenton reaction cascade
GPX4 Specific Activity (% basal at 48h)18% ± 3% (Severe depletion)76% ± 5% (Preserved)85% ± 4% (Functional rescue)Indicates capacity to detoxify cytotoxic membrane-bound phospholipid hydroperoxides
4-HNE Protein Adduct Accumulation>4.2-fold elevation<1.4-fold (Suppressed)<1.3-fold (Suppressed)Quantifies cytotoxic electrophilic Michael additions damaging SERCA2a and troponin I
In Vitro Cardiomyocyte Rescue (Viability %)Baseline cytotoxic driver82% ± 4% at 10 μM94% ± 3% at 1 μMValidates iron chelation and radical-trapping over apoptotic caspase pathway targeting

Note: All binding affinities and enzymatic rates determined via radioligand displacement, electron paramagnetic resonance, and spectrophotometric lipid oxidation kinetics.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

What is the significance of Redox Cycling and Mitochondrial Bioenergetic Collapse?Mechanism of Action

Doxorubicin-mediated cardiotoxicity originates from single-electron reduction of its quinone moiety by mitochondrial NADH dehydrogenase (Complex I) and NADPH-dependent oxidoreductases, producing a transient semiquinone radical intermediate.

What is the significance of Biphasic Keap1-Nrf2 Dysregulation and Antioxidant Collapse?Pharmacological Potency

The endogenous response to doxorubicin exposure displays biphasic activation-to-repression kinetics centered on the Kelch-like ECH-associated protein 1 (Keap1) and nuclear factor erythroid 2-related factor 2.

References

  1. [1]. Yoshikawa N, et al. Cardio-Oncology. 2024;10(1).
  2. [2]. Liu C, et al. Advanced Science. 2023;10(30).
  3. [3]. Vitale R, et al. International Journal of Molecular Sciences. 2024;25(13):7477. [IF: 4.9]
  4. [4]. Zhao X, et al. Cell Death Discovery. 2023;9(1). [IF: 6.1]
  5. [5]. Chen W, et al. ESC Heart Failure. 2025;12(3):1807-1817. [IF: 3.7]
  6. [8]. Wu L, et al. JACC: Basic to Translational Science. 2024;9(6):811-826.
  7. [6]. Bai X, et al. PLOS ONE. 2025;20(2):e0319067. [IF: 2.6]
  8. [7]. Zhang G, et al. Frontiers in Cardiovascular Medicine. 2022;9. [IF: 3.6]
  9. [9]. Xie L, et al. Journal of Traditional and Complementary Medicine. 2025;15(5):573-581. [IF: 3.0]